Trouble reading this email? View it in your browser
European Federation of Pharmaceutical industries and associations
   

EFPIA Newsletter 11 May 2023

 
 
 
   

Blog

 

AMR and its impact on solid organ transplant recipients
11 May 2023 - Luciano Potena - Devi Mey

AMR is a significant public health concern that can have a significant impact on the health outcomes of solid organ... Read more

 
 
 
   

The AMR challenge

 
Jo Atkinson and the threat of AMR
Investing in R&D for new antimicrobials is key to provide patients with better tools to fight resistant bacteria. ... Read more

Driving R&D to tackle AMR
Dr. Liz Rhee, Vice President and Head, Infectious Disease Clinical Research, MSD discusses the importance of innovation... Read more

 
 
 
   

Events

 

Revealing policy barriers in diabetes care: How we can improve outcomes
24 May 2023 (Online)

An event by PwC & EFPIA Read more

Realising the potential of the European Health Data Space for Innovation
30 May 2023 (Residence Palace, Rue de la Loi 155, 1040 Brussels)

EFPIA and COPAC are pleased to invite you to an in-person discussion on the key issues that are fundamental in ensuring... Read more

 
 
 
   

Faster, more equitable access to medicines across Europe

EFPIA’s 2022 Patient WAIT Indicator tracks the availability of new medicines and length of time it takes patients to get them in 37 countries in the EU and EEA. Figures show that, on average, a new medicine will reach patients fastest in Germany in 128 days; this compares with 918 days in Romania and 1351 days in Malta, with a European average of 517 days. 

In Europe, the average rate of availability of medicines across all therapy areas has dropped to 47% - down 2% on last year’s figures. Disparities persist between Northern and Western Europe and Southern and Eastern Europe - with an 80% average variance in availability. 

Find out more about our commitments to help reduce patient access inequalities.
 
 
 
 
   

What we are reading

 
Impact of Multiple Sclerosis Symptoms (IMSS) survey among People with MS in Europe
On 11 May 2023 (Survey)

The European Multiple Sclerosis Platform (EMSP) is leading on a pan-European survey to understand in depth the symptoms... Read more

Farmaci, riforma UE. Moll (EFPIA): più equilibrio tra proprietà intellettuale e accesso a cure...
On 10 May 2023 (Sanita33)

EFPIA DG Nathalie Moll talks about the recently published EU pharmaceutical legislation. Read more